<DOC>
	<DOCNO>NCT02470663</DOCNO>
	<brief_summary>Patients diagnose , risk osteoporosis regularly take calcium dietary supplement , although contribution BMD maintenance , prevention bone loss reduction risk fracture questionable . Freshwater crayfish rely amorphous calcium carbonate ( ACC ) , thermodynamically instable rare biomineralized polymorph calcium carbonate , main mineral exoskeleton temporary storage organ , gastrolith . The study hypothesis amorphous calcium carbonate ( ACC ) advantage calcium carbonate improve BMD pediatric IBD patient reduce BMD . The investigator include child 10-18 year old IBD reduce bone density recieve regular calcium amorphic calcium 12 month follow bone density confounders disease activity medication .</brief_summary>
	<brief_title>Bone Density Children With IBD Treated With Amorphous Calcium Commercial Crystalline Calcium</brief_title>
	<detailed_description>Abstract- Scientific Background Inflammatory bowel disease ( IBD ) , include Crohn 's disease ( CD ) ulcerative Colitis ( UC ) chronic disorder gastrointestinal tract define relapse remit episode . One concern comorbidities IBD reduce bone mineral density ( BMD ) . Recent study report 43 % -46 % child CD BMD z-scores &lt; _1 SD diagnosis ( 1.2 ) BMD improve treatment IBD . Chronic inflammation adverse effect skeletal muscle health child IBD multiple mechanism . Emerging data suggests increase risk vertebral fracture patient ( 3 ) . In longitudinal study , Children IBD significantly low mean BMD z score lumbar spine ( LS ) baseline 2 year . The reduction occur UC CD , neither improve z score follow-up ( 4 ) . Patients diagnose , risk osteoporosis regularly take calcium dietary supplement , although contribution BMD maintenance , prevention bone loss reduction risk fracture questionable . Freshwater crayfish rely amorphous calcium carbonate ( ACC ) , thermodynamically instable rare biomineralized polymorph calcium carbonate , main mineral exoskeleton temporary storage organ , gastrolith . Preclinical study reveal increase calcium gastrointestinal bioavailability , bone absorption retention rat administer ACC compare calcium supplementation . ACC 's beneficial effect bone loss prevention , bone formation bone mechanical strength maintenance , also demonstrate ovaryectomy rat model . A clinical study conduct 13 postmenopausal woman reveal 2 fold increase calcium gastrointestinal bioavailability ACC compare Calcium Carbonate ( 5,6 ) . α-Klotho ( klotho ) transmembrane protein cleave shed act circulate hormone ( 7 ) , essential cofactor bind fibroblast growth factor ( FGF ) cognate receptor , serve major regulator phosphate homeostasis ( 8 ) . Low klotho level recently note adolescent anorexia nervosa ( 9 ) . Hypothesis 1 . Amorphous calcium carbonate ( ACC ) advantage calcium carbonate improve BMD pediatric IBD patient reduce BMD . 2 . Serum klotho level reduce time IBD diagnosis increase follow weight rehabilitation . Furthermore , klotho level associate bone density activity GH/IGF-1 axis . Study Aims 1 . To compare effectiveness amorphous calcium calcium carbonate supplementation MBD improvement child IBD osteopenia/osteoporosis . 2 . To compare tolerability amorphous calcium calcium carbonate child . 3 . To assess Klotho level correlation anthropometric measurement , IGF-I level , BMD Z-score , study entry completion . Experimental Design Prospective randomize multicenter investigator blind trial , include 4 pediatric gastroenterology unit . Study population - Children 10-18 year age inflammatory bowel disease ( CD , UC , IBD-U ) , prove baseline osteopenia osteoporosis , measure lumbar spine Z-score low -1.0 ( minus 1.0 ) Inclusion criterion : 1 . Children 10-18 year old . 2 . Confirmed diagnosis IBD 3 . Able swallow pill . 4 . Osteopenia osteoporosis ( spine Z score lower -1.0 ) baseline bone scan . 5 . Informed consent . Exclusion criterion : 1 . Inadequate bone marrow , renal hepatic function . 2 . Significant concurrent disease . 3 . Allergy calcium vitamin D preparation . 4 . Pathologic hypercalciuria . 5 . Patient non-compliance . 6 . Pregnancy . Randomization coding : All site provide cod numbered opaque envelope . The envelope contain patient code randomization group 1 group 2 . The envelope must open sequentially , informed consent obtain . Patients may redistribute treatment arm reallocate envelope open . All randomization envelope store safe place remain unopened patient randomize . Blinding : This investigator-blinded study . A pre-packed box require medication give subject inform consent sign . A nurse physician involve study address question provide instruction . Study medication treatment duration : Study medication - DENSITYTM caplets ( marketed Amorphical ) 200 mg BID . Control medication - Calcium carbonate 600 mg daily DENSITYTM provide Amorphical company . Vitamin D supplementation - give patient accord baseline serum level follow- , achieve sufficient level . Treatment duration - 52 week . Monitoring - 1 . Laboratory tests- Serum calcium , PTH , phosphor , vitamin D - baseline , 16 , 32 , 52 week . Urinary calcium ( 24 hour ) - week 0 , 4 , 16 52 treatment . Serum urine bone turnover marker - baseline 52 week . 2 . Disease activity- PCDAI , visit - every 8-12 week 3 . Medications record - especially systemic topical steroid use 4 . Diet- dairy product dietary calcium consumption assess questionnaire - baseline , week 16 , 32 , 52 . 5 . Compliance - assess visit , question pill count . 6 . Bone mineral density ( BMD ) - perform baseline week 52 . BMD lumbar spine ( L1-L4 ) hip evaluate use DXA ( Lunar Prodigy ; GE Medical Systems , Madison , WI , USA ) . BMD express gram per square centimeter term Z-scores ( i.e . difference BMD patient average BMD age- sex-matched control divide standard deviation control group ) . All BMD test perform Sheba medical center interpret physician , blinded medication use . 7 . Klotho IGF-1 level - obtain baseline 52 week ( Samples klotho IGF-1 measurement centrifuge 15 minute 2700 rpm , separate , frozen -70ºC use . Klotho level analyze use α-klotho ELISA kit ( Immuno-Biological Laboratories Co , Japan ) . The kit validate widely use measurement klotho level ( 10,11 ) . IGF-1 measured chemiluminescent immunometric method ( Immulite 2000 , Siemens Medical Solutions Diagnostics , Los Angeles , CA , USA ) . 8 . Adverse events- follow week 60 . Primary endpoint The primary efficacy endpoint improvement spine bone density 0.5 point Z -score 12 month . Secondary endpoint 1 . Improvement spine bone density least 0.25 point Z -score 12 month . Sample size Sample size calculate base assumption primary endpoint achieve 20 % patient standard calcium+D , supplementation 40 % patient study medication . The sample size 50 patient arm .</detailed_description>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . Children 1018 year old . 2 . Confirmed diagnosis IBD 3 . Able swallow pill . 4 . Osteopenia osteoporosis ( spine Z score lower 1.0 ) baseline bone scan . 5 . Informed consent . 1 . Inadequate bone marrow , renal hepatic function . 2 . Significant concurrent disease . 3 . Allergy calcium vitamin D preparation . 4 . Pathologic hypercalciuria . 5 . Patient noncompliance . 6 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>